课题基金 / 基金详情

Autocrine growth inhibitors of keratinocytes and their significance in carcinogenesis

Autocrine growth inhibitors of keratinocytes and their significance in carcinogenesis
角质形成细胞自分泌生长抑制剂及其在癌变中的意义
批准号:
09670243
负责人:
KATO Mitsuyasu
金额:
$2.37万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
1997
资助国家:
日本
项目状态:
已结题
起止时间:
1997 至 1998

项目摘要

项目成果

KATO Mitsuyasu的其他基金

相似基金

相关文献

中文摘要
翻译
(1) TGF-β途径限制性SMAD的功能:我们鉴定了Smad2的剪接变体,其省略了外显子3。当使用p3TP-lux作为报告基因时,Smad2DELTAexon3的转录活性比野生型Smad2更有效,并且与Smad3相似。Smad2DELTAexon3具有与p3TP启动子中的Smad结合元件结合的活性,Smad3可以结合该元件,但Smad2不能。这些结果表明Smad2外显子3编码的肽干扰了Smad2与DNA的直接结合。我们还发现HaCaT细胞中TGF-β同时激活Smad2和Smad3,激活素激活Smad3的效果与TGF-β一样强,但激活素对Smad2的激活不如TGF-β激活。(2)突变型Smad3对TGF-β信号的抑制:在结肠癌病例中发现的 Smad2 突变是在 Smad3 的相应残基上重建的。该突变体 Smad3D407E 对 TGF-β 信号具有显性负作用。Smad3D407E 的表达赋予 HaCaT 细胞侵袭性生长潜力以及对 TGF-β 生长抑制作用的抵抗力。(3) 癌细胞中 TGF-β 信号的破坏:甲状腺乳头状微腺癌患者原发灶中TGF-β染色阳性的患者远处转移发生率高于阴性病例。(4)TGF-β信号的靶基因:c-Myc被鉴定为角化细胞中TGF-β生长抑制信号中SMADs的重要靶标。我们还鉴定了一个新的TGF-β早期反应基因。该基因编码19 kDa的核蛋白,等电点为10.9。(5) TGF-β的生理功能TGF-β信号:TGF-β被认为参与角膜伤口愈合过程中的上皮细胞迁移。
英文摘要
(1) Functions of TGF-beta pathway-restricted SMADs : We identified a splice variant of Smad2 which omitted exon 3.Smad2DELTAexon3 had a transcriptional activity more potent than wild-type Smad2 and similar to Smad3, when p3TP-lux was used as a reporter.Smad2DELTAexon3 had an activity to bind to a Smad binding element in the p3TP promoter, which Smad3 can bind to but Smad2 can not.These results suggested that the peptide coded by exon 3 of Smad2 interfered with the direct DNA binding of Smad2.We also found that TGF-beta activated both Smad2 and Smad3 in HaCaT cells, and activin activated Smad3 as potent as TGF-beta did, but the activation of Smad2 by activin was less potent than that by TGF-beta.(2) Inhibition of TGF-beta signals by a mutant Smad3 : A mutation of Smad2 identified in a case of colon cancer was reconstructed on the corresponding residue of Smad3.This mutant Smad3D407E had a dominant negative effect on TGF-beta signals.Expression of Smad3D407E conferred invasive growth potential on HaCaT cells as well as resistance to the growth inhibitory effects of TGF-beta.(3) Disruption of TGF-beta signals in cancer cells : Patients of papillary thyroid microadenocarcinoma with a positive staining for TGF-beta in the primary lesions had higher incidence of distant metastasis than negative cases.(4) Target genes of TGF-beta signals : c-Myc was identified to be an essential target of SMADs in growth inhibitory signals of TGF-beta in keratinocytes.We also identified a new early responsive gene to TGF-beta.This gene coded a nuclear protein of 19 kDa with an isoelectric point of 10.9.(5) Physiological function of TGF-beta signals : TGF-beta was suggested to be involved in epithelial cell migration during the corneal wound healing process.
期刊论文(27)
专著(0)
科研奖励(0)
会议论文
Sugitani I et al: "Clinicopathologic and immunohistochemical studies of papillary thyroid microcarcinoma with clinically apparent cervical lymphadenopathy." World J.Surg.22. 731-737 (1998)
Sugitani I 等人:“具有临床明显颈部淋巴结肿大的甲状腺微小乳头状癌的临床病理学和免疫组织化学研究。”
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Furue M et al: "Dysregulated expression of transforming growth factor beta (TGF-beta) and its type I and type II receptors in basal cell carcinoma" Int.J.Cancer. 71. 505-509 (1997)
Furue M 等人:“基底细胞癌中转化生长因子 β (TGF-β) 及其 I 型和 II 型受体的表达失调”Int.J.Cancer。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Yamashita H et al.: "Growth/differentiation factor-5 induces angiogenesis in vivo." Exp.Cell Res.235. 218-226 (1997)
Yamashita H 等人:“生长/分化因子 5 诱导体内血管生成。”
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Yagi,K.et al.: "Alternatively-Spliced variant of Smad2 lacking exon 3 : comparison with wild-type Smad2 and Smad3." The Journal of Biological Chemistry. 274. 703-709 (1999)
Yagi,K.et al.:“缺少外显子 3 的 Smad2 的选择性剪接变体:与野生型 Smad2 和 Smad3 的比较。”
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
24
    Induction of Cancer Stem Cell Properties by GPNMB
    • 批准号:
      18H02676
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $11.15万
    • 财政年份:
      2018
    • 负责人:
      KATO Mitsuyasu
    • 依托单位:
    Tumorigenic activity of tissue-specific oncogene THG-1
    • 批准号:
      25640059
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.58万
    • 财政年份:
      2013
    • 负责人:
      KATO Mitsuyasu
    • 依托单位:
    Translational TGF-β Research for Diagnosis, Treatment, and Prevention of Cancer
    • 批准号:
      21390115
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $11.73万
    • 财政年份:
      2009
    • 负责人:
      KATO Mitsuyasu
    • 依托单位:
    Transcriptional regulation of the target genes of transforming growth factor-β and it's abnormalities in disease.
    • 批准号:
      14570208
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.62万
    • 财政年份:
      2002
    • 负责人:
      KATO Mitsuyasu
    • 依托单位:
    国内基金
    海外基金
    脊髓电刺激活化Na(V)1.1阳性GABA神经元持续缓解癌痛
    • 批准号:
      82371223
    • 项目类别:
      面上项目
    • 资助金额:
      49.00万元
    • 批准年份:
      2023
    • 负责人:
      闻大翔
    • 依托单位:
    5'-tRF-GlyGCC通过SRSF1调控RNA可变剪切促三阴性乳腺癌作用机制及干预策略
    • 批准号:
      82372743
    • 项目类别:
      面上项目
    • 资助金额:
      49.00万元
    • 批准年份:
      2023
    • 负责人:
      陈卓佳
    • 依托单位:
    丁酸梭菌代谢物(如丁酸、苯乳酸)通过MYC-TYMS信号轴影响结直肠癌化疗敏感性的效应及其机制研究
    • 批准号:
      82373139
    • 项目类别:
      面上项目
    • 资助金额:
      48.00万元
    • 批准年份:
      2023
    • 负责人:
      李孟鸿
    • 依托单位:
    均相液相生物芯片检测系统的构建及其在癌症早期诊断上的应用
    • 批准号:
      82372089
    • 项目类别:
      面上项目
    • 资助金额:
      48.00万元
    • 批准年份:
      2023
    • 负责人:
      李万万
    • 依托单位: